BIT
OREX

BlackRock Institutional Trust’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BlackRock Institutional Trust’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$372K Hold
213,649
– – ﹤0.01% 3503
2016
Q3 		$709K Sell
213,649
-3
-0% -$11 ﹤0.01% 3400
2016
Q2 		$919K Sell
213,652
-99,293
-32% -$449K ﹤0.01% 3335
2016
Q1 		$1.76M Sell
312,945
-6,183
-2% -$80.3K ﹤0.01% 3091
2015
Q4 		$5.49M Buy
319,128
+38,098
+14% +$908K ﹤0.01% 2673
2015
Q3 		$5.93M Sell
281,030
-9,318
-3% -$319K ﹤0.01% 2622
2015
Q2 		$14.4M Sell
290,348
-29,662
-9% -$1.77M ﹤0.01% 2151
2015
Q1 		$25.1M Buy
320,010
+2,138
+0.7% +$133K ﹤0.01% 1798
2014
Q4 		$19.3M Sell
317,872
-25,157
-7% -$1.26M ﹤0.01% 1937
2014
Q3 		$14.6M Buy
343,029
+27,749
+9% +$1.49M ﹤0.01% 2083
2014
Q2 		$19.5M Buy
315,280
+17,477
+6% +$1.02M ﹤0.01% 1978
2014
Q1 		$19.4M Buy
297,803
+14,590
+5% +$987K ﹤0.01% 1984
2013
Q4 		$15.9M Buy
283,213
+7,224
+3% +$406K ﹤0.01% 2108
2013
Q3 		$16.9M Buy
275,989
+10,081
+4% +$683K ﹤0.01% 1988
2013
Q2 		$15.5M Buy
+265,908
New +$16.4M ﹤0.01% 2007

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

BlackRock Institutional Trust's OREX Position: Q4 2016 in Review

BlackRock Institutional Trust held its Orexigen Therapeutics, Inc. (OREX) position steady in Q4 2016 at 213,649 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #3503.

BlackRock Institutional Trust first reported a position in OREX in Q2 2013 and has held it in 15 quarters since. The position peaked at $25.1M in Q1 2015. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

  • BlackRock Institutional Trust held 213,649 shares of Orexigen Therapeutics, Inc. worth $372K as of Q4 2016.
  • BlackRock Institutional Trust left its Orexigen Therapeutics, Inc. share count unchanged in Q4 2016.
  • Orexigen Therapeutics, Inc. made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3503 holding.
  • BlackRock Institutional Trust first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Orexigen Therapeutics, Inc. position peaked at $25.1M in Q1 2015.
  • 53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.